Background: Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information.
Introduction
Antibody inhibitors of programmed-death receptor 1 (PD1) have become a standard treatment of patients with advanced melanoma. The PD1 inhibitors pembrolizumab and nivolumab improve response rates (RRs), progression-free survival (PFS) and overall survival (OS) in melanoma patients compared with chemotherapy and the CTLA4 inhibitor, ipilimumab [1] [2] [3] . Despite the impressive activity of these drugs, 40%-60% of patients do not respond [4] .
There is therefore an urgent need to identify biomarkers that accurately predict for treatment response in melanoma patients receiving PD1 inhibitors, either alone or in combination with ipilimumab. Currently, the tumour-associated expression of PD-L1 and the distribution and density of tumour infiltrating lymphocytes are commonly examined in immune therapy based trials [5] . The clinical utility of these markers is limited due to inter-and intra-patient heterogeneity [6] , and they may require repeat, invasive biopsies. RRs in melanoma patients treated with PD1 inhibitors range from 26% to 57.5% in PD-L1 positive tumours and 15% to 41.3% in PD-L1 negative tumours at baseline, and thus, PD-L1 expression cannot be used to exclude patients from receiving PD1 inhibitors [3, [7] [8] [9] .
Circulating tumour DNA (ctDNA) is associated with baseline tumour burden [10] and melanoma patients with low baseline ctDNA have better response and longer PFS with MAPK inhibitors, independent of LDH and tumour stage. Moreover, a fall in ctDNA during treatment is an independent predictor of response to MAPK inhibitors in melanoma [10, 11] . In this study, we examined whether ctDNA levels at baseline and early during therapy could predict response and clinical outcome of PD1 inhibitors or combination PD1 inhibitors and ipilimumab in a large prospective cohort of metastatic melanoma patients.
Materials and methods

Patients and treatment
Patients with stage IV melanoma with established mutations (BRAF, NRAS, KIT) and treated with immunotherapy at Westmead Hospital and Melanoma Institute Australia between July 2014 and December 2015 were included in this study. Written consent was obtained from all patients under approved Human Research ethics committee protocols from Royal Prince Alfred Hospital (Protocol X15-0454 & HREC/11/RPAH/444). Patients were treated with pembrolizumab or nivolumab monotherapy at currently approved doses, or in combination with ipilimumab. Dosing regimens were according to FDA approved doses of single agent PD1 antibodies or the combination was administered according to the schedule in the ABC or MK3475-029 clinical trials (NCT02374242, NCT02089685) [9, 12] . A validation cohort was identified as patients treated at Melanoma Institute Australia between January 2015 and May 2016.
Disease characteristics and response assessment
Patient demographics and clinicopathologic features including Eastern Cooperative Oncology Group (ECOG) performance status, LDH levels at baseline, mutation status and American Joint Committee on Cancer (AJCC) M stage were collected. Baseline disease burden was determined by the sum of the product of bi-dimensional diameters (SPOD) for every metastasis 5mm in long axis (15mm short axis for lymph nodes). A SPOD 1000 mm 2 was considered low disease burden and >1000 mm 2 was considered high disease burden based on the median. Investigator-determined objective response was assessed radiologically with computed tomography scans alone or where indicated, with magnetic resonance imaging of the brain, at two to three monthly intervals using RECIST 1.1 criteria [13] . Patients who did not have restaging imaging due to clinical disease progression as assessed by their primary clinician, were classified as progressive disease (PD) and included in the analysis.
Statistical analysis
Patient characteristics and clinical parameters including LDH, disease volume, AJCC M stage and ECOG were summarised by the three ctDNA patient groups. Frequencies and percentages by group along with their corresponding P values of the v 2 test or Fisher's exact test as appropriate are reported in Table 1 . Correlation between variables was estimated using linear regression models [14] . Time-to-event outcomes, PFS and OS were described via the Kaplan-Meier method from the start of therapy to the date of first reported PD or death for PFS and death for OS. PFS and OS survival curves were stratified by baseline and on-therapy ctDNA and compared using the Log-rank test.
The ctDNA was dichotomised as detectable and undetectable to discriminate between good and poor responders. Multivariate regression analysis included ctDNA, LDH, disease volume, ECOG and AJCC tumour stage variables. Cox regression was carried out for OS and logistic regression was used for objective response and 6-month PFS.
Analyses were carried out using Graphpad Prism 7 and R 3.3.1.
Results
Patient characteristics
A total of 86 patients with metastatic melanoma were included in this study; 50 patients received PD1 inhibitors alone and 36 were treated with combination PD1 inhibitors and ipilimumab (Table 1) . Median follow-up duration was 17.5 months (range 10.5-28 months); 63 (73%) patients were alive at time of analysis and 45 (52%) patients had ongoing treatment response. For the total cohort, the RR was 53%, the 1 year PFS was 51% and 1 year OS was 77%. A total of 263 plasma samples were collected, including a baseline sample for all 86 patients, collected 0-28 days prior to therapy initiation. Longitudinal samples were obtained for 78/86 (91%) patients, collected over several time points up to 12 weeks from treatment commencement ( Figure 1) .
Ten of 86 patients were excluded from further evaluation: 5 patients had rapid clinical progression and death with no samples available on therapy, 2 patients had a baseline blood draw while receiving combination dabrafenib and trametinib, and 3 patients did not undergo any blood draws prior to week 12 (blood collected at weeks 16, 16 and 20) . ctDNA analyses of baseline and on-therapy samples revealed three distinct patient profiles. Profile group A (n ¼ 36) consisted of patients with undetectable ctDNA levels at baseline and during therapy. Group B (n ¼ 22) had detectable baseline ctDNA but became undetectable early during therapy, with 20/22 patients zero converting within the week 5-8 of therapy. Group C (n ¼ 18) had detectable ctDNA at baseline and during therapy, up until and including week 12.
Clinical characteristics across the three ctDNA patient groups were similar for age, sex, tumour stage, prevalence of brain metastases and mutational distribution (Table 1 ). An undetectable ctDNA at baseline (group A) was associated with a lower disease volume (supplementary Figure S1A , available at Annals of Oncology online). In the 46 patients with a positive ctDNA, ctDNA counts and tumour volume were correlated (R 2 ¼ 0.2665, P < 0.001) (supplementary Figure S1B , available at Annals of Oncology online).
Prognostic value of ctDNA groups
Objective response. The RR at first restaging was significantly higher in group A and B patients when compared with group C patients [26/36 (72%), 17/22 (77%), 1/18 (6%) respectively, Table 2 ]. A complete response at first scan was seen in three patients, all of which were in group A ( Table 2) . Of the 18 patients in group C, 4 patients had a > 50% reduction of ctDNA level within 12 weeks of treatment; 1 patient had a partial response and 3 patients had stable disease. The sensitivity, specificity, and positive and negative predictive value for undetectable ctDNA at baseline or on therapy for response at week 12 was 79%, 94%, 98% and 59%, respectively.
A total of eighteen patients had intracranial metastases at baseline, with isolated intracranial progression observed in 8/18 (45%) patients; 6 in group A and 2 in group B. When patients were assessed for extracranial response only, the RRs in groups A and B improved to 89% and 86%, respectively (supplementary Table S1 , available at Annals of Oncology online).
Progression free and overall survival. Group A and B patients had a significantly longer PFS than group C patients (Figure 2A ). Median PFS was not reached for groups A and B, but was 2.7 months for group C. The hazard ratio (HR) was 0.08 (95% CI 0.03-0.2, P < 0.001) for group A and 0.15 (95% CI 0.03-0.18, P < 0.001) for group B when compared with group C. There was no statistically significant difference observed between groups A and B. ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; PD1, programmed cell death protein-1; LDH, lactate dehydrogenase; SPOD, sum of product of diameters. a 10 patients were not stratified in to the above 3 groups: 5 patients only had rapid disease progression and no available on-therapy samples, 3 patients had no on-therapy samples before week 12 and 2 patients had baseline samples collected while on MAPK inhibitor therapy. b The P value was calculated using the Freeman-Halton extension of the Fisher exact probability test for a two rows by three columns contingency At the time of data cut-off, there were 16 deaths, all related to disease except 1 patient who died from sepsis secondary to lower respiratory tract infection. Median OS was not reached for group A and B patients, but was 9.8 months for group C patients ( Figure 2B ). The HR was 0.11 (95% CI 0.03-0.27, P < 0.001) for group A and 0.12 (95% CI 0.05-0.43, P < 0.001) for group B when compared with group C.
Univariate analysis revealed an association between OR and disease volume (odds ratio 2.87, P ¼ 0.04) and tumour stage (odds ratio 3.72, P ¼ 0.034), and OS with ECOG performance [11] [12] ctDNA copies per ml plasma 10 000+ 1000 -10 000 100 -1000 10 -100 1 -10 Undetectable Figure 1 . Overview of ctDNA results (copies/ml plasma) and RECIST response at first restaging in 76 melanoma patients. Each column is an individual patient, demonstrating longitudinal, quantitative ctDNA results up to week 12 and RECIST response at first restaging imaging (median days to first scan 81 days). Patients were stratified in to three ctDNA profile Groups; Group A, undetectable ctDNA at baseline which remained undetectable during therapy; Group B, detectable ctDNA at baseline which zero-converted during therapy; Group C, detectable ctDNA at baseline which remained detectable during therapy. Abbreviations: CR, complete response; PR partial response; SD, stable disease; PD, progressive disease. The two-sided P value was calculated using Fisher's exact probability test for a two by two contingency table.
status (HR 0.14, P ¼ 0.002) (supplementary Table S2 , available at Annals of Oncology online). Because groups A and B were associated with similar RRs, PFS and OS, these groups were combined for multivariate Cox regression analysis including LDH and the above mentioned variables. This revealed that an undetectable ctDNA at baseline or during therapy (groups A and B) remained significant for response, PFS and OS (Table 3) . When multivariate analysis was carried out for baseline ctDNA only (group A compared with groups B and C combined), there was no association with survival when adjusted for clinical variables (supplementary Table S3 , available at Annals of Oncology online). The association of ctDNA and LDH as time-dependent variable on OS using a Landmark analysis from baseline to week 12 in sequential weekly intervals, demonstrated that ctDNA was superior in predicting 12 months OS at every time point (supplemen tary Figure S2 , available at Annals of Oncology online).
Validation cohort
We confirmed our findings in an independent validation cohort of 29 patients with stage IV melanoma receiving anti-PD1 alone or in combination with anti-CTLA4. Patients with predominant brain metastases were not included in the validation cohort. The sensitivity of ctDNA at baseline was 66% and ORR were 70% in group A (10 patients; compared with 89% RR in discovery cohort), 91% in group B (11 patients; 86% RR in discovery cohort) and 0% in group C (8 patients; 6% RR in discovery cohort). One patient in group A, with SD, and one group B patient who had PD on first scan, subsequently achieved partial responses, demonstrating a flare phenomenon/pseudoprogression (supplemen tary Figure S3 , available at Annals of Oncology online). The predictive value for objective response by first scan in patients in groups A or B compared with group C was also statistically significant [OR 66.1 (95% CI 3.2-1374.5); P < 0.01]. 
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Discussion
This study shows that a favourable ctDNA profile, defined here as undetectable ctDNA levels at baseline or within 8 weeks of therapy, is an independent predictor of response and prolonged survival in melanoma patients treated with PD1 inhibitor-based immunotherapy. ctDNA was superior to other baseline clinical parameters associated with response and prognosis, including LDH, disease burden and ECOG performance status. We suggest that ctDNA profile at 8 weeks is a sensitive and reliable biomarker to use in PD1 antibody-based trials. Early response data may allow for the early initiation of salvage therapy, for example, the addition of an agent to the backbone of PD1 inhibitor. One such study currently underway is assessing the efficacy of the combination ipilimumab/nivolumab after failure of single agent PD1 antibodies (NCT02731729).
Baseline ctDNA is a useful measure of potential response, but is not independent of other clinical parameters such as baseline LDH and disease volume. This presumably reflects the established association between baseline ctDNA and tumour burden [10] , and the fact that patients with lower disease burden have higher RRs to immunotherapy [15] . When longitudinal measurement of ctDNA and LDH were compared with predict 1-year OS in our cohort, an undetectable ctDNA remained significant at all landmark points as opposed to a normal LDH, which became non-significant beyond week 4. It is important to recognise, however, that only 37% of our patients had an elevated LDH, and none had an LDH >2.5 xULN, thus limiting the utility of LDH as a predictive biomarker in this patient subset. Thus, taken together with previous reports, it is possible that variable LDH provides additional predictive information. ctDNA profiles in patients with predominant brain metastases were not accurate predictors of objective response: 14/18 patients with predominant brain metastases were classified as groups A or B and yet their RR was only 43%. This observation questions the utility of ctDNA quantification in the case of predominant brain metastases [11, 16] , and is consistent with previous studies suggesting that the blood barrier may prevent ctDNA from entering the circulation.
Currently the most investigated biomarker of anti-PD1 response is baseline tumour PD-L1 expression by immunohistochemistry. The limitation of PD-L1 expression is low specificity, only 62%-72% across trials, compared with 92% specificity for the ctDNA model proposed here [3, 7] . Increase in CD8þ T cell density from baseline to early treatment also correlates with anti-PD1 response and survival [17, 18] . Furthermore, baseline intratumoural PD1þ T cell density was higher in responders compared with non-responders [5] and correlated with degree of radiological response [18] . Unlike ctDNA, on therapy tumour biomarkers require multiple biopsies, lesions may not always be accessible, and a single biopsy may not account for patient and tumour heterogeneity [6] .
There has been much interest in the analysis of routine clinical parameters, such as median tumour size [19] , haematological parameters [20] and LDH [21] to predict response to PD1 inhibitors. In a recent study, melanoma patients with four favourable baseline factors (LDH < 2.5 xULN, limited visceral tumour burden and high relative neutrophil and eosinophil counts), had 1-year overall survival after pembrolizumab of 83.9% versus only 14.7% in patients with none of these four favourable factors [20] . Although these data are comparable to our ctDNA signature, in the multiparameter model, only 12.7% of patients were in the most favourable group, limiting the ability of such clinical parameters to identify a substantial fraction of patients with a high likelihood of response. In fact, none of our 105 patients had an unfavourable LDH >2.5 xULN.
There is a clear relationship between baseline ctDNA levels and disease volume [10] and although we confirm this association, we noted only a weak relationship between baseline ctDNA and tumour burden. We hypothesize that this may reflect previous systemic therapy, as 37/86 (43%) patients in our cohort received prior MAPK treatment. This raises the possibility that ctDNA may reflect cellular proliferation rather than simply disease volume, with additional research and analyses on the way.
While it may appear that a limitation of ctDNA analysis is the low level of baseline ctDNA detectability (56% in our cohorts, n ¼ 105), ddPCR is extremely sensitive and reproducible [22] and low or undetectable ctDNA levels are predictive of response outcome [10, 11] . Importantly, our rate of detection is lower than current reports, presumably because we applied a detection threshold of three positive mutant DNA droplets to ensure specificity [23] . When all mutant droplets were considered, ctDNA was detected in 73% of our patients combined, a detection rate equivalent to similar melanoma studies [10, 11, 23, 24] . 
